ResMed Inc. — Form 10-Q summary
Business context and period: ResMed designs and sells sleep and respiratory care devices and operates software-as-a-service (SaaS) platforms for out-of-hospital care providers. This unaudited report covers the three months ended September 30, 2023, ResMed’s fiscal 2024 first quarter, compared with the three months ended September 30, 2022. Amounts below are in U.S. dollars.
Financial performance
| Metric | Quarter ended Sep. 30, 2023 | Prior-year quarter | Change |
|---|---|---|---|
| Revenue | $1,102.3 million | $950.3 million | +16% reported; +15% constant currency |
| Gross profit / margin | $600.1 million / 54.4% | $540.8 million / 56.9% | Profit +11%; margin down 2.5 percentage points |
| Operating income | $289.0 million | $275.7 million | +5% |
| Net income | $219.4 million | $210.5 million | +4% |
| Diluted EPS | $1.49 | $1.43 | +4% |
| Cash from operating activities | $286.3 million | $44.7 million | Increased $241.6 million |
| Capital expenditures | $30.0 million | $29.1 million | — |
- Revenue mix: Sleep and Respiratory Care revenue was $963.0 million, up 14% (13% constant currency). SaaS revenue was $139.3 million, up 32%; excluding MEDIFOX DAN, acquired in November 2022, SaaS revenue grew 7%.
- Cash and liquidity: Cash and equivalents were $209.1 million at September 30, down from $227.9 million at June 30, 2023. Cash plus available revolver capacity totaled $1,034.1 million; $825.0 million remained available under the revolving facility. Management said existing liquidity sources should fund operations and expected capital expenditures for the next 12 months and beyond.
- Debt: Total debt was $1,365.0 million outstanding under the revolving and term credit facilities and senior notes; balance-sheet debt, net of borrowing costs, was $1,361.4 million. The variable-rate credit facility and term debt carried a 6.3% rate at quarter-end. The company reported covenant compliance.
- Other balance-sheet items: Total assets were $6.741 billion and stockholders’ equity was $4.250 billion. Current assets were $2.305 billion and current liabilities $770.8 million.
- Cash flow: Investing used $149.0 million, including $103.2 million for business acquisitions, net of cash acquired. Financing used $151.1 million, including $185.0 million of debt repayments, $105.0 million of borrowings, and $70.6 million of dividends. Cash declined $18.8 million overall.
Changes, outlook and risks
- Revenue growth was driven by higher device and mask sales, attributed primarily to increased demand and unit sales. Masks and other revenue rose 22%; device revenue rose 9%. Europe, Asia and other markets grew 22% reported and 18% constant currency.
- Gross margin fell primarily because of higher component and manufacturing costs and a $7.9 million provision for an Astral ventilation-device field safety notification. Favorable product mix and currency partly offset the pressure. Excluding acquired-intangible amortization and the Astral provision, non-GAAP gross margin was 56.0%, versus 57.6% a year earlier.
- Operating cash flow improved mainly due to lower inventory-purchase cash outflows and greater customer receipts. Interest expense increased to $15.0 million from $7.1 million, reflecting higher debt associated with MEDIFOX DAN financing.
- Management described continued AirSense 11 rollout and ongoing investment in product development, digital health and SaaS. The filing provides no specific numerical revenue or earnings guidance.
- Contingencies and risks: The Astral notification concerns replacement of a component in certain devices manufactured from 2013 to 2019; the recorded estimate was $7.9 million. ResMed reported ongoing patent litigation, including NYU and Cleveland Medical matters, and said it could not reasonably estimate potential losses for open matters. It did not expect litigation outcomes to materially affect the consolidated financial statements as a whole. The filing identifies foreign-exchange, interest-rate, inflation, supply-chain, reimbursement, regulatory and other risks; it reported no material changes to the risk factors in its fiscal 2023 Form 10-K.
- The board declared a $0.48-per-share dividend payable December 14, 2023. In October 2023, the company announced plans to resume share repurchases; none occurred during the reported quarter.
Investor facts to verify
- Whether demand and unit growth continue across devices, masks and regions, and whether SaaS growth excluding MEDIFOX DAN is sustained.
- Whether gross-margin pressure from manufacturing and component costs eases, and whether Astral notification costs remain within the recorded estimate.
- Whether operating cash flow remains strong as inventory and working-capital patterns change.
- Debt repayment, variable interest expense, revolver availability and covenant compliance.
- Developments and potential financial exposure in the NYU and Cleveland Medical litigation; the filing does not provide a clear estimate of losses for open matters.